A Case of Pulmonary Leiomyoma in a Renal Transplanted Patient.
- Author:
Sun Jin YOU
1
;
Sungjin CHUNG
;
Il KIM
;
Hwan Cheol PARK
;
Yeo Wook YUN
;
Chang Hwa LEE
;
Kyung Won KAHNG
;
Jong Myoung KANG
;
Moon Hyang PARK
Author Information
1. Department of Internal Medicine, School of Medicine, Hanyang University, Seoul, Korea. kangjm@hanyang.ac.kr
- Publication Type:Case Report
- Keywords:
Renal transplantation;
Smooth muscle tumor;
Immunosuppressants;
Epstein-barr virus (EBV)
- MeSH:
Adult;
Biopsy;
Colon;
Cyclosporine;
Diagnosis;
DNA;
Herpesvirus 4, Human;
Humans;
Immunoglobulins;
Immunosuppressive Agents;
Incidence;
Kidney Transplantation;
Leiomyoma*;
Lung;
Male;
Smooth Muscle Tumor;
Thorax;
Tomography, X-Ray Computed;
Ultrasonography
- From:Korean Journal of Nephrology
2003;22(6):767-772
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The overall incidence of malignancy in a renal transplanted patient is 3 to 5 times higher compared with general population. We report a very rare case of multiple leiomyoma originated from lung after renal transplantation. 33-year-old male underwent renal transplantation in November, 1989. A 5 mm sized pulmonary nodule was found in the left lower lobe incidentally in March, 2001. The size of pulmonary nodule increased and same lesion was found on the opposite side of the lung on chest roentgenogram after one year, so we proceeded with computed tomography of the chest. Variable sized multiple nodules in the whole lung field were noted, which were thought be metastatic lesions, and for detection of the primary site of malignancy, further study including esophagogastroduodenoscope, colon study, abdominal ultrasound, abdominal CT, bone scan and tumor marker were checked, but there was no evidence of primary cancer. After open lung biopsy low malignant potential smooth muscle tumor was noted, and Epstein-barr virus (EBV) DNA was detected. The patient had been maintained on immunosuppressive therapy with cyclosporine and mycophenolate mofetil (MMF), and after the diagnosis of leiomyoma administration of MMF was stoped, and cyclosporine dosage was reduced. With the reduction of immunosuppressants, intravenous immunoglobulin trial was done for the first cycle, but the efficacy of treatment is not clear.
